



# A study on risk factors eliciting opioid adverse reactions in elderly males

Jiyoung Kim<sup>1</sup>, Soo Jin Song<sup>1</sup>, Youn-joo Jung<sup>1</sup>, Hyekeun Jeong<sup>1</sup>

Joo Hee Kim<sup>2</sup>, Jeong Yee<sup>2</sup>, Hye Sun Gwak<sup>2</sup>

<sup>1</sup> Department of Pharmacy, Veterans Health Service Medical Center, Seoul, Korea

<sup>2</sup> College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea

## Background and Purpose

Opioid administration for pain control and relevant reports of adverse reactions have rapidly increased in the last several decades. In particular, elderly patients with various underlying disorders are administered with multiple drugs and prone to drug-drug interactions, and special attention is necessary in prescribing opioids. This study attempts to verify the incidence rates of opioid adverse reactions, the symptomatic manifestations, and examine causative factors in elderly male patients.

## METHOD


This retrospective study, conducted via electronic medical records, included a total of 320 male patients, 65 years old or older, who had been prescribed with oral opioids in this hospital from January 1 to December 31, 2012. These subjects were divided into two groups: Group one for patients with adverse reaction manifestations (ARM) and another group for patients with no ARM. The correlations with age, body mass index, alcohol drinking and smoking, underlying diseases, previous opioid usage and concurrently-administered drugs were analyzed.

## RESULT


### Result 1 ) Baseline characteristics (total n=320)

Characteristics		Mean±SD/No(%)
Age (years)		70.9±5.7(65.0-88.0)
Height (cm)		164.9±5.6(136.0-179.3)
Weight (kg)		65.7±10.8(40.4-97.0)
BMI (kg/m <sup>2</sup> )		24.2±3.6(15.2-37.5)
Alcohol	Yes	97 (32.6)
	No (past)	201 (67.4)
Smoking	Yes	73 (24.2)
	No (past)	229 (75.8)
Underlying disease	Gastrointestinal disease	286 (89.4)
	Cardiovascular disease	247 (77.2)
	Cancer	136 (42.5)
	Endocrine disease	135 (42.2)
	Hepatic disease	38 (11.9)
	Renal disease	30 (9.4)
Indication	Cancer pain	81 (25.3)
	Dyspnea	61 (19.1)
	Back pain	52 (16.3)
	Neuralgia	52 (16.3)
	Operation pain	6 (1.9)
	Traumatic pain	5 (1.6)
	Chest pain	1 (0.3)
	Others	61 (19.1)
Duration	< 90days	198 (61.9)
	≥ 90days	122 (38.1)
Previous opioid	Yes	196 (61.3)
	No	124 (38.8)
Opioid type	Codein	94 (29.4)
	Codein+fentanyl	4 (1.3)
	Codein+oxycodone	8 (2.5)
	Fentanyl	4 (1.3)
	Fentanyl+oxycodone	10 (3.1)
	Morphine	78 (24.4)
	Morphine+oxycodone	10 (3.1)
	Oxycodone	111 (34.7)
Combination	Opioid	33 (10.3)
	Tramadol, fentanyl patch	145 (45.3)
	GABA analogue (gabapentin, pregabalin)	161 (50.3)
	NSAIDs	145 (45.3)
	TCA (amitriptyline)	85 (26.8)
	Benzodiazepine	93 (29.1)

### Result 2-1 ) Percentage of patients developed adverse reactions



### Result 2 -2) Type of adverse reactions



### Result 3-1 ) Multivariate analysis of factors affecting adverse drug reactions- Model I

Characteristics	Unadjusted OR (95%CI)	Model I Adjusted OR (95%CI)
Age (≥70)	0.983 (0.599-1.614)	
Cancer	0.312 (0.179-0.542)	0.305 (0.145-0.642)
Endocrine disease	1.938 (1.182-3.177)	
Duration (≥90days)	2.328 (1.413-3.834)	2.127 (1.137-3.980)
Previous opioid	1.549 (0.923-2.601)	
TCA	1.675 (0.980-2.862)	
GABA analogue	4.439 (2.565-7.682)	
Benzodiazepine	1.933 (1.151-3.248)	
Codeine	1	1
Morphine	13.755 (5.030-37.608)	7.520 (2.547-22.208)
Oxycodone	8.197 (3.059-21.968)	7.259 (2.545-20.701)

### Result 3 -2) Multivariate analysis of factors affecting adverse drug reactions- Model II

Characteristics	Unadjusted OR (95%CI)	Model II Adjusted OR (95%CI)
Age (≥70)	0.983 (0.599-1.614)	
Cancer	0.312 (0.179-0.542)	0.323 (0.169-0.617)
Endocrine disease	1.938 (1.182-3.177)	
Duration (≥90days)	2.328 (1.413-3.834)	2.054 (1.149-3.673)
Previous opioid	1.549 (0.923-2.601)	
TCA	1.675 (0.980-2.862)	
GABA analogue	4.439 (2.565-7.682)	3.259 (1.777-5.977)
Benzodiazepine	1.933 (1.151-3.248)	
Combination	2.399 (1.151-5.000)	2.793 (1.089-7.163)

## CONCLUSIONS

In elderly male patients with opioid administration, factors that relatively lower development of adverse reactions were malignancy and codeine. Administrations of long-term opioid, concurrent GABA analogue and multiple opioids increase adverse reactions. Further investigation is necessary to overcome the limitation of this retrospective study and to include factors that had not been fully scrutinized yet.

## Acknowledgements

Thanks to our head of pharmacy department and hospital officials who have extended helping hands for this study.



Corresponding author : Jiyoung Kim, Department of pharmacy, Veterans Health Service Medical Center, 53, Jinhwangdo-ro 61-gil, 05368, Gangdong-gu, Seoul, Korea  
E-mail : jy8099@bohun.or.kr

https://doi.org/10.29328/issn.2474-2990

ABSTRACT NUMBER: SPSQ-080